Synthesis and antiprotozoal activity of n -alkoxy analogues of the trypanocidal lead compound 4,4′-bis(imidazolinylamino)diphenylamine with improved human blood-brain barrier permeability

Journal of Medicinal Chemistry

Volumn 54, Issue 2, 2011, Pages 485-494

  Nieto, Lidia ^a   Mascaraque, Ainhoa ^a   Miller, Florence ^b,c   Glacial, Fabienne ^b,c   Ríos Martínez, Carlos ^a   Kaiser, Marcel ^d,e   Brun, Reto ^d,e   Dardonville, Christophe ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b INSTITUT COCHIN   (France)

^c INSERM   (France)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' BIS(IMIDAZOLINYLAMINO)DIPHENYLAMINE; ANTITRYPANOSOMAL AGENT; ORGANOLEAD COMPOUND; THIOUREA; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CHEMICAL REACTION; CONTROLLED STUDY; CYCLIZATION; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; TRYPANOSOMA RHODESIENSE;

ANIMALS; ANTIMALARIALS; BLOOD-BRAIN BARRIER; CELL LINE; DIPHENYLAMINE; HUMANS; IMIDAZOLINES; LEISHMANIA DONOVANI; MICE; PERMEABILITY; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS, AFRICAN;

EID: 78751674927     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101335q     Document Type: Article

References (53)

1. Human African Trypanosomiasis: Global View. http://www.dndi.org/diseases/ hat/global-view.html (accessed 25th November 2009).
2. WHO. Human African Trypanosomiasis (Sleeping Sickness): Epidemiological Update. Wkly Epidemiol. Rec. 2006, 81, 71 - 80.
3. WHO. Control and Surveillance of African Trypanosomiaisis; WHO Technical Report Series, Vol. 881; World Health Organization: Geneva, 1998; pp 1 - 113.
4. Rodgers, J. Human African trypanosomiasis, chemotherapy and CNS disease J. Neuroimmunol. 2009, 211, 16-22
5. Barrett, M. P.; Boykin, D. W.; Brun, R.; Tidwell, R. R. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br. J. Pharmacol. 2007.
6. Dardonville, C.; Brun, R. Bisguanidine, bis(2-aminoimidazoline), and polyamine derivatives as potent and selective chemotherapeutic agents against Trypanosoma brucei rhodesiense. Synthesis and in vitro evaluation J. Med. Chem. 2004, 47, 2296-2307
7. Rodríguez, F.; Rozas, I.; Kaiser, M.; Brun, R.; Nguyen, B.; Wilson, W. D.; García, R. N.; Dardonville, C. New Bis(2-aminoimidazoline) and Bisguanidine DNA Minor Groove Binders with Potent in Vivo Antitrypanosomal and Antiplasmodial Activity J. Med. Chem. 2008, 51, 909-923
8. Glass, L. S.; Nguyen, B.; Goodwin, K. D.; Dardonville, C.; Wilson, W. D.; Long, E. C.; Georgiadis, M. M. Crystal Structure of a Trypanocidal 4,4′-Bis(imidazolinylamino)diphenylamine Bound to DNA Biochemistry 2009, 48, 5943-5952
9. Dardonville, C.; Barrett, M. P.; Brun, R.; Kaiser, M.; Tanious, F.; Wilson, W. D. DNA binding affinity of bisguanidine and bis(2-aminoimidazoline) derivatives with in vivo antitrypanosomal activity J. Med. Chem. 2006, 49, 3748-3752
10. Kinsella, G. K.; Rodriguez, F.; Watson, G. W.; Rozas, I. Computational approach to the basicity of a series of [alpha]1-adrenoceptor ligands in aqueous solution Bioorg. Med. Chem. 2007, 15, 2850-2855
11. Riggs, J. R.; Kolesnikov, A.; Hendrix, J.; Young, W. B.; Shrader, W. D.; Vijaykumar, D.; Stephens, R.; Liu, L.; Pan, L.; Mordenti, J. Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability Bioorg. Med. Chem. Lett. 2006, 16, 2224-2228 (Pubitemid 43351083)
12. Clement, B.; Mau, S.; Deters, S.; Havemeyer, A. Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N -hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2 s)-2-[[4-[(hydroxyamino) iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid) Drug Metab. Dispos. 2005, 33, 1740-1747
13. Clement, B. Reduction of N -hydroxylated compounds: amidoximes (N -hydroxyamidines) as pro-drugs of amidines Drug Metab. Rev. 2002, 34, 565-79
14. Boykin, D. W.; Kumar, A.; Hall, J. E.; Bender, B. C.; Tidwell, R. R. Prodrugs for aromatic bis-amidines: anti-pneumocystis activity of bis-amidoximes and bis-alkylamidoximes. Abstracts of Papers of the American Chemical Society, Vol. 214; American Chemical Society: Washington, DC, 1997; 162 -Medi.
15. Boykin, D. W.; Kumar, A.; Hall, J. E.; Bender, B. C.; Tidwell, R. R. Anti-pneumocystis activity of bis-amidoximes and bis- O -alkylamidoximes prodrugs Bioorg. Med. Chem. Lett. 1996, 6, 3017-3020
16. Thuita, J. K.; Karanja, S. M.; Wenzler, T.; Mdachi, R. E.; Ngotho, J. M.; Kagira, J. M.; Tidwell, R.; Brun, R. Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis Acta Trop. 2008, 108, 6-10
17. Mdachi, R. E.; Thuita, J. K.; Kagira, J. M.; Ngotho, J. M.; Murilla, G. A.; Ndungu, J. M.; Tidwell, R. R.; Hall, J. E.; Brun, R. Efficacy of the novel diamidine compound 2,5-bis(4-amidinophenyl)-furan-bis- O -methlylamidoxime (pafuramidine, DB289) against T. b. rhodesiense infection in vervet monkeys after oral administration Antimicrob. Agents Chemother. 2009, 53, 953-957
18. Huang, T. L.; Bacchi, C. J.; Kode, N. R.; Zhang, Q.; Wang, G.; Yartlet, N.; Rattendi, D.; Londono, I.; Mazumder, L.; Vanden Eynde, J. J.; Mayence, A.; Donkor, I. O. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug Int. J. Antimicrob. Agents 2007, 30, 555-561
19. Ismail, M. A.; Brun, R.; Easterbrook, J. D.; Tanious, F. A.; Wilson, W. D.; Boykin, D. W. Synthesis and antiprotozoal activity of aza-analogues of furamidine J. Med. Chem. 2003, 46, 4761-4769
20. Wenzler, T.; Boykin, D. W.; Ismail, M. A.; Hall, J. E.; Tidwell, R. R.; Brun, R. New Treatment Option for Second-Stage African Sleeping Sickness: In Vitro and In Vivo Efficacy of Aza Analogs of DB289 Antimicrob. Agents Chemother. 2009, 53, 4185-4192
21. Weller, T.; Alig, L.; Beresini, M.; Blackburn, B.; Bunting, S.; Hadvary, P.; Muller, M. H.; Knopp, D.; Levet-Trafit, B.; Lipari, M. T.; Modi, N. B.; Muller, M.; Refino, C. J.; Schmitt, M.; Schonholzer, P.; Weiss, S.; Steiner, B. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines J. Med. Chem. 1996, 39, 3139-3147
22. Degardin, M.; Wein, S.; Durand, T.; Escale, R.; Vial, H.; Vo-Hoang, Y. N -Substituted bis- C -alkyloxadiazolones as dual effectors: efficient intermediates to amidoximes or amidines and prodrug candidates of potent antimalarials Bioorg. Med. Chem. Lett. 2009, 19, 5233-5236
23. Reeh, C.; Wundt, J.; Clement, B. N, N ′-Dihydroxyamidines: A New Prodrug Principle To Improve the Oral Bioavailability of Amidines J. Med. Chem. 2007, 50, 6730-6734
24. Dennis, S.; Joscha, K.; Helen, H.; Jürke, K.; Bernd, C. The Peptidylglycine alpha-Amidating Monooxygenase (PAM): A Novel Prodrug Strategy for Amidoximes and N -Hydroxyguanidines? ChemMedChem 2009, 4, 1595-1599
25. Clement, B.; Burenheide, A.; Rieckert, W.; Schwarz, J. Diacetyldiamidoximeester of pentamidine, a prodrug for treatment of protozoal diseases: synthesis, in vitro and in vivo biotransformation ChemMedChem 2006, 1, 1260-1267
26. Grimmett, M. R. Imidazoles and their benzo derivatives: (ii) Reactivity. In Comprehensive Heterocyclic Chemistry: Pergamon: Elmsford, NY, 1984; Vol. 5, p 384.
27. Metzger, J. V. Thiazoles and their benzo derivatives. In Comprehensive Heterocyclic Chemistry, Pergamon: Elmsford, NY, 1984; Vol. 6, p 252.
28. Poller, B.; Gutmann, H.; Krähenbühl, S.; Weksler, B.; Romero, I.; Couraud, P.-O.; Tuffin, G.; Drewe, J.; Huwyler, J. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies J. Neurochem. 2008, 107, 1358-1368
29. Weksler, B. B.; Subileau, E. A.; Perriere, N.; Charneau, P.; Holloway, K.; Leveque, M.; Tricoire-Leignel, H.; Nicotra, A.; Bourdoulous, S.; Turowski, P.; Male, D. K.; Roux, F.; Greenwood, J.; Romero, I. A.; Couraud, P. O. Blood-brain barrier-specific properties of a human adult brain endothelial cell line FASEB J. 2005, 19, 1872-1874
30. Cucullo, L.; Couraud, P.-O.; Weksler, B.; Romero, I.-A.; Hossain, M.; Rapp, E.; Janigro, D. Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies J. Cereb. Blood Flow Metab. 2007, 28, 312-328
31. Dauchy, S.; Miller, F.; Couraud, P. O.; Weaver, R. J.; Weksler, B.; Romero, I. A.; Scherrmann, J. M.; De Waziers, I.; Decleves, X. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells Biochem. Pharmacol. 2009, 77, 897-909
32. Hill, S. V.; Thea, S.; Williams, A. Degradation in aqueous solution of O -aryl N -arylthioncarbamates to aryloxide ions and isothiocyanates. A study of Leffler′s assumption J. Chem. Soc., Perkin Trans. 2 1983, 437-446
33. Ramuz, H. 2-Imino-imidazolidine derivatives. U.S. Patent 4,244,957, 1978.
34. Alanine, A.; Bourson, A.; Buttelmann, B.; Gill, R.; Heitz, M. P.; Mutel, V.; Pinard, E.; Trube, G.; Wyler, R. 1-Benzyloxy-4,5-dihydro-1 H -imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists Bioorg. Med. Chem. Lett. 2003, 13, 3155-3159 (Pubitemid 37093819)
35. Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis. 3rd ed.; Wiley Intersciences: New York, 1999.
36. Mascaraque, A.; Nieto, L.; Dardonville, C. Efficient one-pot synthesis of 1-alkoxy-2-arylaminoimidazolines from N -alkoxy- N -(2-aminoethyl)-2- nitrobenzenesulfonamides and arylisothiocyanates Tetrahedron Lett. 2008, 49, 4571-4574
37. Dardonville, C.; Fernandez-Fernandez, C.; Gibbons, S. L.; Jagerovic, N.; Nieto, L.; Ryan, G.; Kaiser, M.; Brun, R. Antiprotozoal activity of 1-phenethyl-4-aminopiperidine derivatives Antimicrob. Agents Chemother. 2009, 53, 3815-3821
38. Cecchelli, R.; Dehouck, B.; Descamps, L.; Fenart, L.; Buée-Scherrer, V.; Duhem, C.; Lundquist, S.; Rentfel, M.; Torpier, G.; Dehouck, M. P. In vitro model for evaluating drug transport across the blood-brain barrier Adv. Drug Delivery Rev. 1999, 36, 165-178
39. Siflinger-Birnboim, A.; del Vecchio, P. J.; Cooper, J. A.; Blumenstock, F. A.; Shepard, J. M.; Malik, A. B. Molecular sieving characteristics of the cultured endothelial monolayer J. Cell. Physiol. 1987, 132, 111-117
40. Deli, M.; Ábrahám, C.; Kataoka, Y.; Niwa, M. Permeability Studies on In Vitro Blood-Brain Barrier Models: Physiology, Pathology, and Pharmacology Cell. Mol. Neurobiol. 2005, 25, 59-127
41. Hall, J. E.; Kerrigan, J. E.; Ramachandran, K.; Bender, B. C.; Stanko, J. P.; Jones, S. K.; Patrick, D. A.; Tidwell, R. R. Anti-pneumocystis activities of aromatic diamidoxime prodrugs Antimicrob. Agents Chemother. 1998, 42, 666-674
42. Dardonville, C.; Rozas, I.; Alkorta, I. Similarity studies on guanidinium, imidazolinium, and imidazolium cations: toward new bradykinin antagonists. J. Mol. Graphics Modell. 1998, 16, 150 - 156, 166 - 167.
43. 2-insensitive NADH-benzamidoxime reductase J. Biol. Chem. 1997, 272, 19615-19620
44. Clement, B.; Demesmaeker, M.; Linne, S. Microsomal catalyzed N -hydroxylation of guanabenz and reduction of the N -hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz Chem. Res. Toxicol. 1996, 9, 682-688
45. Perriere, N.; Yousif, S.; Cazaubon, S.; Chaverot, N.; Bourasset, F.; Cisternino, S.; Decleves, X.; Hori, S.; Terasaki, T.; Deli, M.; Scherrmann, J. M.; Temsamani, J.; Roux, F.; Couraud, P. O. A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters Brain Res. 2007, 1150, 1-13
46. Hitchcock, S. A.; Pennington, L. D. Structure-Brain Exposure Relationships J. Med. Chem. 2006, 49, 7559-7583
47. Mensch, J.; Oyarzabal, J.; Mackie, C.; Augustijns, P. In vivo, in vitro and in silico methods for small molecule transfer across the BBB J. Pharm. Sci. 2009, 98, 4429-4468
48. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, O. A. Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and Shape, and H-Bonding Descriptors J. Drug Targeting 1998, 6, 151-165
49. Rozalska, I.; Kulyk, P.; Kulszewicz-Bajer, I. Linear 1,4-coupled oligoanilines of defined length: preparation and spectroscopic properties New J. Chem. 2004, 28, 1235-1243
50. Raz, B.; Iten, M.; Grether-Buhler, Y.; Kaminsky, R.; Brun, R. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro Acta Trop. 1997, 68, 139-147
51. OBrien, J.; Wilson, I.; Orton, T.; Pognan, F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity Eur. J. Biochem. 2000, 267, 5421-5426
52. Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique Antimicrob. Agents Chemother. 1979, 16, 710-718
53. Buckner, F. S.; Verlinde, C. L.; La Flamme, A. C.; Van Voorhis, W. C. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase Antimicrob. Agents Chemother. 1996, 40, 2592-2597